drugset
drugset / Trial / NCT00863460

Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

NCT00863460 ↗

Phase 2 Unknown 140 enrolled Institut Curie Amgen · collabHoffmann-La Roche · collabMinistry of Health, France · collabPierre Fabre Laboratories · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Purpose of the study : To evaluate the antitumoral effect of two therapeutic procedures and to evaluate their respective toxicity on the CNS.

Timeline

Start
2008-10-03
Primary completion
2016-05-17
Completion
2026-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule 0.8 mg/kg Intravenous
Subject Cyclophosphamide Other / unclassified 60 mg/kg Intravenous
Subject Thiotepa Other / unclassified 250 mg/m2 Intravenous
Background Cytarabine Small molecule 3 g Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Methotrexate Small molecule 3 g Intravenous
Background Prednisone Other / unclassified 60 mg/m2 Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background carmustine Small molecule 100 mg/m2 Intravenous

Indications

primary central nervous system lymphoma